Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003829 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00003829 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 34 participants.
The verdict
NCT00003829, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Alternating treatment with more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of fludarabine alternating with cyclophosphamide in treating patients who have previously untreated chronic lymphocytic leukemia.
Interventions
- DRUG cyclophosphamide
- DRUG fludarabine phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 1999-08 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003829
The ClinicalTrials.gov registry entry for NCT00003829 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cyclophosphamide is the first listed.
NCT00003829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003829 about?
NCT00003829 is a clinical study titled "Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Alternating treatment with more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of fludarabine alternating with cyclophosphamide in t...
What is the current status of trial NCT00003829?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 1999-08. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00003829?
The interventions under investigation include: cyclophosphamide (DRUG), fludarabine phosphate (DRUG).
Who is sponsoring clinical trial NCT00003829?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.